Exec Chat: Catching Up With Drug-Device Developers Sequana At LSX

The company’s dual drug-device development pipeline is progressing well, with the company expecting its device, the Alfapump, to hit US clinics in 2025.  

• Source: Shutterstock

Sequana Medical is working on both device and drug-based approaches to dealing with fluid overload in the body.

Recently, Sequana was awarded FDA clearance for an investigational new drug application (IND) of its direct sodium removal (DSR) 2.0...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Brazil Asks Stakeholders To Weigh In On Ways To Improve Country’s Trial Environment

 

Brazil is planning to update its National Clinical Research Action Plan to make the country a more competitive location to conduct R&D.

Abbott’s Navitor TAVR Wins CE Mark Expansion, New Guidelines Allow Treatment For Younger Patients

 
• By 

Abbott’s Navitor TAVR system is now CE-marked for low to intermediate risk patients, based on positive data from the Vintage trial. The EACTS guidelines for TAVR lowered the recommended age for patients with severe aortic stenosis to 70 years and older, which opens up treatment for younger patients.

Government-Backed UK Network Enhances Access To Clinical Trials

 
• By 

The UK government expects that its new nation-wide network will enable companies to set up clinical trials more quickly and expand access to diverse patient populations across the National Health Service.

SetPoint Medical Raises $140M: Pipeline Expansion And Multiple Sclerosis Clinical Trial On Horizon

 

SetPoint Medical secured US FDA approval for its vagus nerve neuromodulation device to treat RA. Now, the start-up is tasked with convincing both rheumatologist and surgeons to adopt its technology over or alongside biologic drugs. CEO Murthy Simhambhatla talks exit strategy plans.

More from R&D

Government-Backed UK Network Enhances Access To Clinical Trials

 
• By 

The UK government expects that its new nation-wide network will enable companies to set up clinical trials more quickly and expand access to diverse patient populations across the National Health Service.

SetPoint Medical Raises $140M: Pipeline Expansion And Multiple Sclerosis Clinical Trial On Horizon

 

SetPoint Medical secured US FDA approval for its vagus nerve neuromodulation device to treat RA. Now, the start-up is tasked with convincing both rheumatologist and surgeons to adopt its technology over or alongside biologic drugs. CEO Murthy Simhambhatla talks exit strategy plans.

German Health Researchers Prep for Possible Disruptions to PubMed, ClinicalTrials.gov

 

IQWiG, Germany’s health technology assessment body, is making contingency plans in case key US resources it relies on for information retrieval, when conducting benefit assessments of new medicines, become unavailable.